Phaseline

Targets › LPIN1

LPIN1 (Phosphatidate phosphatase LPIN1): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Respiratory; next expected readout Nov 2026.

Acts as a magnesium-dependent phosphatidate phosphatase enzyme which catalyzes the conversion of phosphatidic acid to diacylglycerol during triglyceride, phosphatidylcholine and phosphatidylethanolamine biosynthesis and therefore controls the metabolism of fatty acids at different levels. Is involved in adipocyte differentiation (By similarity). (UniProt, Q14693)

Open in Phaseline: the race on LPIN1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Calluna PharmaCAL101
LPIN1 inhibitor
LPIN1Phase 2Idiopathic Pulmonary FibrosisNov 2026

Conditions

Idiopathic Pulmonary Fibrosis (1)

Modalities

small molecule (1)

Companies

Calluna Pharma (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.